A New Chapter in Headache Research: What This Merging of Minds Means for Migraine Sufferers The merger between Fulcrum Therapeutics and Slate Medicines has injected new energy into migraine research, a field that sorely needs innovation.
The deal's impressive $245 million private placement, led by prominent healthcare investors, underscores the industry's growing interest in tackling this complex condition.
Slate Medicines' CEO Gregory Oakes aims to revolutionize migraine treatment – an ambitious goal considering the millions of people worldwide affected and underserved by current therapies.